Non-Rash Dermatologic Adverse Events Related to Targeted Therapies

Dy, 2013, Understanding, recognizing, and managing toxicities of targeted anticancer therapies, CA Cancer J Clin, 63, 249, 10.3322/caac.21184 Belum, 2013, Skin toxicity of targeted cancer agents: mechanisms and intervention, Future Oncol, 9, 1161, 10.2217/fon.13.62 Fecher, 2013, Ipilimumab and its toxicities: a multidisciplinary approach, Oncologist, 18, 733, 10.1634/theoncologist.2012-0483 Lacouture, 2011, Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities, Support Care Cancer, 19, 1079, 10.1007/s00520-011-1197-6 Mandala, 2013, Cutaneous toxicities of BRAF inhibitors: clinical and pathological challenges and call to action, Crit Rev Oncol Hematol, 88, 318, 10.1016/j.critrevonc.2013.06.002 Manousaridis, 2013, Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management, J Eur Acad Dermatol Venereol, 27, 11, 10.1111/j.1468-3083.2012.04546.x Peuvrel, 2012, Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors, Support Care Cancer, 20, 909, 10.1007/s00520-012-1404-0 Joshi, 2010, Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life, Cancer, 116, 3916, 10.1002/cncr.25090 Rosen, 2013, Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic, Am J Clin Dermatol, 14, 327, 10.1007/s40257-013-0021-0 White, 2011, Psychosocial impact of cutaneous toxicities associated with epidermal growth factor receptor-inhibitor treatment, Clin J Oncol Nurs, 15, 88, 10.1188/11.CJON.88-96 Ensslin, 2013, Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis, J Am Acad Dermatol, 69, 708, 10.1016/j.jaad.2013.06.038 Wu, 2011, Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors, Curr Opin Oncol, 23, 343, 10.1097/CCO.0b013e3283474063 Esper, 2007, What kind of rash is it?: deciphering the dermatologic toxicities of biologic and targeted therapies, Clin J Oncol Nurs, 11, 659, 10.1188/07.CJON.659-666 Eaby, 2008, An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors, Clin J Oncol Nurs, 12, 283, 10.1188/08.CJON.283-290 Boucher, 2011, Preemptive management of dermatologic toxicities associated with epidermal growth factor receptor inhibitors, Clin J Oncol Nurs, 15, 501, 10.1188/11.CJON.501-508 Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, Version 4.03. May 28, 2009. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (accessed May 5, 2014.) Chen, 2012, Grading dermatologic adverse events of cancer treatments: the common terminology criteria for adverse events. Version 4.0, J Am Acad Dermatol, 67, 1025, 10.1016/j.jaad.2012.02.010 Lacouture, 2010, A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group, Support Care Cancer, 18, 509, 10.1007/s00520-009-0744-x Wagner, 2013, The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18), Support Care Cancer, 21, 1033, 10.1007/s00520-012-1623-4 Boers-Doets, 2013, Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous adverse events, Support Care Cancer, 21, 1919, 10.1007/s00520-013-1752-4 Hay, 2014, Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), Qual Life Res, 23, 257, 10.1007/s11136-013-0470-1 Fischer, 2013, Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4, Dermatol Ther, 26, 135, 10.1111/dth.12027 Belum, 2013, Dermatological adverse events from BRAF inhibitors: a growing problem, Curr Oncol Rep, 15, 249, 10.1007/s11912-013-0308-6 Robert, 2012, Advances in the management of cutaneous toxicities of targeted therapies, Semin Oncol, 39, 227, 10.1053/j.seminoncol.2012.01.009 Osio, 2009, Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors, Br J Dermatol, 161, 515, 10.1111/j.1365-2133.2009.09214.x Balagula, 2010, Dermatologic toxicities of targeted anticancer therapies, J Support Oncol, 8, 149 Burtness, 2009, NCCN Task Force Report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer, J Natl Compr Canc Netw, 7, S5, 10.6004/jnccn.2009.0074 Tarhini, 2013, Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management, Scientifica (Cairo), 2013, 857519 Gandhi, 2010, Unanticipated toxicities from anticancer therapies: survivors’ perspectives, Support Care Cancer, 18, 1461, 10.1007/s00520-009-0769-1 Sinha, 2012, Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities, Br J Dermatol, 167, 987, 10.1111/bjd.12010 Delgado, 2013, Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia, J Am Acad Dermatol, 69, 839, 10.1016/j.jaad.2013.07.025 Robert, 2011, RAF inhibition and induction of cutaneous squamous cell carcinoma, Curr Opin Oncol, 23, 177, 10.1097/CCO.0b013e3283436e8c Mitchell, 2007, Clinical presentation and pathophysiology of EGFRI dermatologic toxicities, Oncology (Williston Park), 21, 4 Sibaud, 2013, [Pigmentary disorders induced by anticancer agents. Part II: targeted therapies], Ann Dermatol Venereol, 140, 266, 10.1016/j.annder.2013.01.442 Kong, 2009, Cutaneous pigmentation after photosensitivity induced by vandetanib therapy, Arch Dermatol, 923, 925 Grande, 2013, Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies, Adv Ther, 30, 945, 10.1007/s12325-013-0069-5 Fabbrocini, 2012, Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors: report of 3 cases, Dermatitis, 23, 237, 10.1097/DER.0b013e31826e45d7 Basti, 2007, Ocular toxicities of epidermal growth factor receptor inhibitors and their management, Cancer Nurs, 30, S10, 10.1097/01.NCC.0000281759.23823.82 Ho, 2013, The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?, Acta Ophthalmologica, 91, 604, 10.1111/j.1755-3768.2012.02518.x Porta, 2009, Tolerability of first-line therapy for metastatic renal cell carcinoma, Cancer Treat Rev, 35, 297, 10.1016/j.ctrv.2008.12.003 Autier, 2008, Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor, Arch Dermatol, 144, 886, 10.1001/archderm.144.7.886 Gore, 2007, Temsirolimus in the treatment of advanced renal cell carcinoma, Ann Oncol, 18, ix87, 10.1093/annonc/mdm299 Motzer, 2007, Sunitinib efficacy against advanced renal cell carcinoma, J Urol, 178, 1883, 10.1016/j.juro.2007.07.030 Sternberg, 2010, Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial, J Clin Oncol, 28, 1061, 10.1200/JCO.2009.23.9764 Novartis Pharmaceuticals Corporation. Full prescribing information: everolimus (AFINITOR®). Available at: http://www.pharma.us.novartis.com/product/pi/pdf/afinitor.pdf (accessed April 15, 2014.) Lee, 2009, Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib, Br J Dermatol, 161, 1045, 10.1111/j.1365-2133.2009.09290.x Wood, 2010, Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors, Commun Oncol, 7, 23, 10.1016/S1548-5315(11)70385-0 Lacouture, 2008, Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib, Oncologist, 13, 1001, 10.1634/theoncologist.2008-0131 Lipworth, 2009, Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib, Oncology, 77, 257, 10.1159/000258880 Sibaud, 2011, HFS-14, a Specific Quality of Life Scale Developed for Patients Suffering from Hand-Foot Syndrome, Oncologist, 16, 1469, 10.1634/theoncologist.2011-0033 Yang, 2010, Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma, Expert Opin Drug Saf, 9, 459, 10.1517/14740331003596349 Dranitsaris, 2012, Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib, Ann Oncol, 23, 2103, 10.1093/annonc/mdr580 Eisen, 2012, Targeted therapies for renal cell carcinoma: review of adverse event management strategies, J Natl Cancer Inst, 104, 93, 10.1093/jnci/djr511 Edmonds, 2012, Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group, Eur J Oncol Nurs, 16, 172, 10.1016/j.ejon.2011.05.001 Boussemart, 2013, Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients, Ann Oncol, 24, 1691, 10.1093/annonc/mdt015 Lacouture, 2013, Analysis of dermatologic events in vemurafenib-treated patients with melanoma, Oncologist, 18, 314, 10.1634/theoncologist.2012-0333 Maldonado-Seral, 2013, Vemurafenib-associated neutrophilic panniculitis: an emergent adverse effect of variable severity, Dermatol Online J, 19, 16, 10.5070/D370X41670 Wnorowski, 2012, The management of EGFR inhibitor adverse events: a case series and treatment paradigm, Int J Dermatol, 51, 223, 10.1111/j.1365-4632.2011.05082.x Jha, 2013, Imatinib-induced Stevens-Johnsons syndrome, BMJ Case Rep, 10.1136/bcr-2012-007926 Sinha, 2014, Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma, Br J Dermatol, 170, 997, 10.1111/bjd.12796 Worswick, 2011, Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options, Dermatol Ther, 24, 207, 10.1111/j.1529-8019.2011.01396.x Koldenhof, 2014, Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions, Support Care Cancer, 10.1007/s00520-014-2223-2